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Dr Elaine Tseng (San Francisco, Calif). You’ve elegantly pre-
sented that EPCs embedded within a fibrin matrix hydrogel after
acute myocardial infarction increased vasculogenesis and
improved cardiac contractility. Stem cells have held significant
promise for the regeneration of cardiac myocardium but have
been fraught with difficulty in cell survival and retention for its
paracrine effects and arrhythmias from direct myocardial injec-
tion. This study is notable for demonstrating the ability of endothe-
lial progenitor stem cells to migrate from the hydrogel into the
injured myocardium after external patch placement of the biocom-
patible matrix.
Previously, not only various types of stem cells but also growth
factors and matrix materials have been investigated. Can you
comment on what might be the ideal combination for use in clin-
ical trials, as your group has investigated these other growth factors
and matrix components.
How do you envision bench-to-bedside translation and for what
population of patients? For example, in this study myocardial
infarction was acute, and this would require some requisite time
for cell and matrix generation before operation versus chronic
heart failure for patients with prior myocardial infarction.
Dr Atluri. I don’t know that we have all the questions answered
in terms of what the optimal components would be. We’ve started
off looking at EPCs, but I do envision a construct that could incor-
porate multiple subcomponents (ie, cytokines, EPCs). I don’t
know that we even have the right phenotype for the EPC yet.
But this is a start, at least, to begin looking at the ability to retain
cells.
In terms of the timing, I think it would be dependent on the com-
ponents. So from a vasculogenic strategy, it clearly makes sense to
think of an acute intervention shortly after a myocardial infarction.
Of course, immediately after a myocardial infarction the cell envi-
ronment is fairly hostile given inflammation in the heart, so that
may provide us the time to isolate cells.
From a chronic standpoint, a vasculogenic strategy does not
make a lot of sense unless you want to preserve purely the border
zone, so I think a myogenic strategy may make sense on a more
chronic model. Of course, then we’re dealing with the problems
that have really plagued us over the last 10 years, which is incor-
poration of muscle or islands of muscle that may bediovascular Surgery c Volume 148, Number 3 1097




Sarrhythmogenic and may not electrically communicate with the
rest of the myocardium itself.
Dr Todd Rosengart (Houston, Tex). Congratulations, it’s good
to see that your group is continuing to focus attention on the ques-
tion of how to improve delivery and retention of delivering exog-
enous cells to the myocardium.
You nicely include a live/dead cell assay, but I was surprised
that you were satisfied with a 50% nonliving cell rate. Having
that data, were you able to isolate those cells and discard them,
or were they included in the injectate?
I was surprised that your cell delivery alone without fibrin did
not result in much of an improvement over controls. I think your
group has previously shown that cells alone, although not ideal,
are still effective. So can you explain?
Dr Atluri. I was a little bit surprised by that data as well. I think
it goes along with some of the clinical findings that were seen in
terms of clinical therapies with isolated EPC therapy. We noticed
small benefits in hemodynamic function. Amajority of the benefits
have been seen from a functional standpoint.
Our group has really seen benefits with cytokine therapy. In
terms of isolated stem cell therapy, we’ve done mesenchymal
stem cells but not isolated EPCs, so we haven’t seen the benefit
with the isolated EPCs.
This is somewhat of a preliminary study.We’ve seen lots of ben-
efits in rodents that have not translated to the clinical arena, so the
next step is to go to a large animal.
I’ve spent a lot of time debating this with my collaborators, the
bioengineers. I don’t know what to make of the 50% viability at 10
days. I think the real analysis is in an in vivo setting rather than in
vitro. I was happy with viability up-front, to know that the fibrin
microenvironment was not hostile immediately to the cells them-
selves. I think the next step would be to look at viability within the
gel in the in vivo implanted model.
Dr Rosengart. So you did not isolate out?
Dr Atluri. I did not isolate out, no.
Dr Bo Yang (Ann Arbor, Mich). Your stem cells treating infarc-
tion has been done clinically by the group at the University of Flor-
ida. They showed good magnetic resonance imaging of the
repopulation of muscle cells, but they didn’t see any improvement
of the ejection fraction. I think that makes sense. Because if you
popularize that scar area, or infarcted area, with muscle cells
from stem cells you still have the ischemia. Your LAD is still1098 The Journal of Thoracic and Cardiovascular Surligated. You have no blood supply to the LAD territory; that’s
why there is no increase of ejection fraction. Your data showed sig-
nificant improvement of the heart function. Do you have an
explanation?
From the catheter system, there are load-independent parame-
ters for the contractility, such as PRA, end-systolic pressure-
volume relationship, and dP/dt versus VED. Why didn’t you
use those parameters instead of ejection fraction, which is a
load-dependent parameter?
Dr Atluri.Yes, we looked at our contractility at the slope of the
end-systolic pressure-volume relationship and tried to eliminate
our load dependence in that situation. I’d put more credibility in
our slope of contractility than I would our ejection fraction, which
is largely a qualitative assay anyways.
Dr Yang. I didn’t see your data or any difference between those
2 groups.
Dr Atluri. There was improved contractility among our 4 treat-
ment groups. There was no difference in contractility with a denser
gel or with more cells that were implanted.
DrYang.The LAD still ligated. Do you have an explanation for
this change of ejection fraction?
Dr Atluri. I think it’s because of the enhanced vasculature from
a microenvironment. You’re right, this is still inferential and it’s
actually a perfusion analysis, so that will be the next step.
Dr John Mayer (Boston, Mass). You didn’t tell us about how
thick the patch is. Could you tell us that?
Dr Atluri. I actually haven’t measured the patch. It’s usually
100 mL that we put onto the Vicryl mesh, so it’s a fairly thin patch.
That’s why I think it’s still a preliminary study because it allows us
to do this on a rodent, and you can still get diffusion nutrients. But
that’s the reason why I don’t think it’s going to be scalable in its
current form to a clinical setting.
Dr Mayer. I would ask you to think about the idea that maybe
what you’re doing is altering the postinfarct inflammatory process
by virtue of this intervention as opposed to necessarily doing
something about the vascular bed immediately. In Juan Melero-
Martin’s studies from our institution where he is creating vascular-
ized implants, it takes days for his Matrigel implants containing
EPCs and mesenchymal stem cells to form a vasculature that con-
nects to the host vasculature. I wonder if there isn’t an alternate
explanation besides just growing more blood vessels.
Dr Atluri. Thank you.gery c September 2014
